Condition: Cerebral Amyloid Angiopathy · Intracerebral Hemorrhage Lobar · Sponsor: Huashan Hospital
The goal of this clinical trial is to assess the safety and tolerability of colchicine for preventing intracerebral haemorrhage (ICH) recurrence in patients with cerebral amyloid angiopathy (CAA)-ICH at high risk of recurrence. The main questions it aims to answer are: * Is colchicine safe for CAA-ICH patients? * Is colchicine well tolerated for CAA-ICH patients? Researchers will compare colchicine to a placebo (a look-alike substance that contains no drug) to see if colchicine is safe and tolerable for CAA-ICH patients and works to prevent ICH recurrence. Participants will: * Take colchicine or a placebo every day for 12 months * Receive telephone follow-ups at 3 and 9 months, and visit the clinic at 6 and 12 months for checkups and tests * Control blood pressure and improve lifestyle
This description comes directly from the study's public registry record.
Xin Cheng, MD, PhD · +86 021-52887145 · chengxin@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, China | Not Yet Recruiting |
| West China Hospital, Sichuan University | Chengdu, China | Not Yet Recruiting |
| Huashan Hospital, Fudan University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07026994